Ephedrine Diphenhydramine Tablets

This product is a compound preparation of ephedrine hydrochloride and diphenhydramine hydrochloride, in which ephedrine hydrochloride can directly stimulate adrenaline receptors, and can also indirectly stimulate adrenaline receptors by prompting adrenergic nerve endings to release norepinephrine, and has a stimulating effect on both alpha receptors and beta receptors. It can dilate bronchi and constrict local blood vessels, and its action time is relatively long; it strengthens myocardial contractility, increases cardiac output, and makes venous return to the heart sufficient; it has a stronger central nervous system excitation effect than adrenaline. Diphenhydramine hydrochloride has ① antihistamine effect, which can compete with histamine released from tissues for H1 receptors on effector cells, thereby stopping allergic reactions; ② at the same time, it inhibits central nervous system activity to cause sedative and hypnotic effects; ③ it strengthens the effect of antitussive drugs.

This product is a compound preparation, each tablet containing 25 mg of ephedrine hydrochloride and 25 mg of diphenhydramine hydrochloride.

Used for bronchial asthma, cough, urticaria, hay fever, allergic rhinitis, etc.

Oral administration: 1-2 tablets at a time, 3-4 times a day, after meals or when an attack occurs.

1. The most common symptoms are lethargy, drowsiness, lack of concentration, and dizziness. 2. It can cause urination difficulties in patients with prostatic hypertrophy. 3. Large doses or long-term use can cause tremors, anxiety, insomnia, headaches, palpitations, tachycardia, etc.

1. Patients who are allergic to any of the ingredients in ephedrine hydrochloride or diphenhydramine hydrochloride are prohibited from using this product. 2. Patients with myasthenia gravis are prohibited from using this product. 3. Patients with arteriosclerosis are prohibited from using this product. 4. Patients with hypertension or angina pectoris are prohibited from using this product. 5. Patients with hyperthyroidism are prohibited from using this product. 6. Neonates and premature infants are prohibited from using this product.

Precautions for children: Forbidden for newborns and premature infants. Precautions for pregnancy and lactation: Forbidden for lactating women.

1. This product can temporarily affect the absorption of barbiturates and sodium sulfacetamide. 2. When used together with sodium para-aminosalicylate, it can reduce the latter's blood concentration. 3. When used together with adrenal cortical hormones, it can increase the latter's metabolic clearance rate, and the dose of corticosteroids must be adjusted. 4. Urine alkalinizing agents, such as antacids, calcium or magnesium carbonates, citrates, sodium bicarbonate, etc., affect the excretion of this product in urine, increase the half-life of this product, and prolong the duration of action. In particular, if the urine remains alkaline for several days or longer, most patients will suffer from ephedrine poisoning, and the dosage of this product should be adjusted. 5. When used together with digitalis glycosides, it can cause arrhythmias. 6. When used together with ergonovine, ergotamine or oxytocin, it can aggravate vasoconstriction, leading to severe hypertension or peripheral tissue ischemia.

Keep away from light and store in sealed container.

Compound

Shanghai Sine Pharmaceutical Laboratories Co., Ltd.

• Founded in:

  1993-10-23

• Address:

  No. 905, Xinjinqiao Road, China (Shanghai) Pilot Free Trade Zone

• Tax NO.:

  91310000133742534B

• Registered Funds:

  1,191,611,312 yuan

• Website:

  Log in to view

• Email:

  Log in to view